<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>The synthetic progestin norgestrel modulates Nrf2 signaling and acts as an antioxidant in a model of retinal degeneration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Byrne, Ashleigh M.; Ruiz-Lopez, Ana M.; Roche, Sarah L.; Moloney, Jennifer N.; Wyse-Jackson, Alice C.; Cotter, Thomas G.</td>
</tr>
<tr>
<td><strong>Publication date</strong></td>
<td>2016-10-04</td>
</tr>
<tr>
<td><strong>Type of publication</strong></td>
<td>Article (peer-reviewed)</td>
</tr>
<tr>
<td><strong>Link to publisher's version</strong></td>
<td><a href="http://dx.doi.org/10.1016/j.redox.2016.10.002">http://dx.doi.org/10.1016/j.redox.2016.10.002</a></td>
</tr>
<tr>
<td>Access to the full text of the published version may require a subscription.</td>
<td></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>).</td>
</tr>
<tr>
<td><strong>Item downloaded from</strong></td>
<td><a href="http://hdl.handle.net/10468/3227">http://hdl.handle.net/10468/3227</a></td>
</tr>
</tbody>
</table>

Downloaded on 2019-01-02T18:11:23Z
Research Paper

The synthetic progestin norgestrel modulates Nrf2 signaling and acts as an antioxidant in a model of retinal degeneration

Ashleigh M. Byrne, Ana M. Ruiz-Lopez, Sarah L. Roche, Jennifer N. Moloney, Alice C. Wyse-Jackson, Thomas G. Cotter⁎

Cell Development and Disease Laboratory, Biochemistry Department, Biosciences Institute, University College Cork, Cork, Ireland

1. Introduction

Retinitis pigmentosa (RP) is one of the most common retinal degenerative conditions affecting people worldwide, and is currently incurable. It is characterized by the progressive loss of photoreceptors, in which the death of rod cells leads to the secondary death of cone cells; the cause of eventual blindness. As rod cells die, retinal-oxygen metabolism becomes perturbed, leading to increased levels of reactive oxygen species (ROS) and thus oxidative stress; a key factor in the secondary death of cones. In this study, norgestrel, an FDA-approved synthetic analog of progesterone, was found to be a powerful neuroprotective antioxidant, preventing light-induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel also prevented light-induced photoreceptor morphological changes that were associated with ROS production, and that are characteristic of RP. Further investigation showed that norgestrel acts via post-translational modulation of the major antioxidant transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increased levels of its effector protein superoxide dismutase 2 (SOD2). In summary, these results demonstrate significant protection of photoreceptor cells from oxidative stress, and underscore the potential of norgestrel as a therapeutic option for RP.

⁎ Corresponding author.
E-mail address: t.cotter@ucc.ie (T.G. Cotter).

http://dx.doi.org/10.1016/j.redox.2016.10.002
Received 15 August 2016; Received in revised form 30 September 2016; Accepted 3 October 2016
Available online 04 October 2016

2213-2317/ © 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by/4.0/).

ARTICLE INFO
Keywords:
Retinitis pigmentosa
Photoreceptors
ROS
Nrf2
Norgestrel

ABSTRACT
Retinitis pigmentosa (RP) is one of the most common retinal degenerative conditions affecting people worldwide, and is currently incurable. It is characterized by the progressive loss of photoreceptors, in which the death of rod cells leads to the secondary death of cone cells; the cause of eventual blindness. As rod cells die, retinal-oxygen metabolism becomes perturbed, leading to increased levels of reactive oxygen species (ROS) and thus oxidative stress; a key factor in the secondary death of cones. In this study, norgestrel, an FDA-approved synthetic analog of progesterone, was found to be a powerful neuroprotective antioxidant, preventing light-induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel also prevented light-induced photoreceptor morphological changes that were associated with ROS production, and that are characteristic of RP. Further investigation showed that norgestrel acts via post-translational modulation of the major antioxidant transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increased levels of its effector protein superoxide dismutase 2 (SOD2). In summary, these results demonstrate significant protection of photoreceptor cells from oxidative stress, and underscore the potential of norgestrel as a therapeutic option for RP.

One of the primary cellular responses to oxidative stress is activation of the ubiquitously expressed basic-leucine-zipper transcription factor NF-E2-related factor-2 (Nrf2) [21,22]. Upon liberation from its repressor, kelch-like ECH-associated protein 1 (KEAP1), Nrf2 translocates into the nucleus where it binds antioxidant response elements (AREs), bringing about the up-regulation of various antioxidant, detoxifying and cytoprotective genes [22–26]. Studies investigating the anti-oxidant effects of Nrf2 in the retina have demonstrated its importance in protecting retinal ganglion cells following optic nerve crush [27], and in slowing the progression of diabetic retinopathy [28]. Although few studies have focused on RP, a recent investigation by Nakagami and colleagues using a rabbit model demonstrated how activation of Nrf2 and upregulation of its effector proteins delayed the loss of photoreceptor cells [29].

Nrf2 can be regulated by various signaling molecules including progesterone, a pleiotropic neuroprotective hormone. It has also been shown that progestin, as part of hormone replacement therapy (HRT), increases the expression of the Nrf2-regulated superoxide dismutase antioxidant enzymes (SODs) [30,31], while in the heart, progesterone upregulates the Nrf2 effector NAD(P)H quinone oxidoreductase 1.
(NQ01) [32]. Progesterone also exerts antioxidant effects in experimental models of traumatic brain injury, which include increasing SOD activity [33–35].

We have previously demonstrated the neuroprotective effects of norgestrel, a synthetic analog of progesterone, in both the inherited RP model, and the light-damage model of retinal degeneration. Norgestrel rescues photoreceptors from cell death via a mechanism which includes upregulation of the neurotrophic factors BFGF and LIF [36,37]. Here, we sought to investigate if the activities of norgestrel in light-induced retinal degeneration include modulation of the redox environment. We provide evidence that norgestrel increases expression and activation of Nrf2 via phosphorylation on serine 40, increases expression of its target antioxidant superoxide dismutase 2 (SOD2), and reduces mitochondrial oxidative stress.

2. Material and methods

2.1. Mice

All animals were maintained and handled in accordance with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. Experiments were performed on balb/c mice obtained from Harlan Olac (Bicester, UK). Mice were euthanized by cervical dislocation. All procedures were approved by the Health Products Regulatory Authority (HPRA), Ireland.

2.2. Light damage model

The light-damage model was performed as previously described [37]. Briefly, Balb/c mice were born into and maintained in dim cyclic light less than 10 lx (12 h on/12 h off). At 4–7 weeks of age, mice were dark adapted for 18 h prior to exposure to damaging light. Mice received intraperitoneal injections (i.p.) of 50 mL (25 mL dimethylsulfoxide/25 mL peanut oil) or 50 mL norgestrel (100 mg/kg), 1 h prior to light-damage. Immediately prior to light-damage, their pupils were dilated with 0.5% cyclopentolate under red light. Retinal light-damage was then induced by exposure to cool white fluorescent light (5000 lx) for 2 h. Following this, the mice were placed in the dark for 6, 24 or 48 h, as indicated, prior to euthanasia.

2.3. Eye sections preparation

Enucleated eyes were fixed in 4% paraformaldehyde (PFA) for 1.5 h followed by cryo-protection in 30% sucrose at 4 °C overnight. Eyes were then frozen in Shandon™ Cryochrom™ (ThermoFisher Scientific) and 7 µm sections were then cut using a cryostat (Leica CM1950; Leica, Nussloch, Germany). Sections were stored at –80 °C until use.

2.4. Microscopy

Retinal sections were viewed using a Leica DM LB2 microscope with Nikon Digital Sight DS-U2 camera, using 40× and 100× objectives. Images were taken using the software NIS-Elements version 3.0, Nikon, Japan. Immunofluorescence on retinal sections was performed on at least three mice of each group, at each time-point. Identical microscope settings were used when obtaining images across all timepoints and treatments. Images shown are those taken of the central retina.

2.5. Quantification from immunohistochemically-labeled sections

Quantification of outer nuclear layer (ONL) thickness and fluorescence intensity measurements were carried out using ImageJ software, as previously described [38,39]. Average ONL thickness was measured by taking measurements from at least 20 sections per mouse. Per section, three distinct measurements were taken and averaged. Nrf2 and SOD2 fluorescence intensity measurements were taken from the same region and in the same orientation, at 40× magnification. These images were used to create plot profiles of the marker of interest and the area under the curve was measured as a readout of fluorescence intensity.

2.6. Apoptosis detection by terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUNEL)

DNA strand breaks in photoreceptor nuclei were detected by terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick end labeling (TUNEL). Frozen sections (7 µm) were incubated with terminal deoxynucleotidyl transferase (Promega, MyBio Ltd., Kilkenny, Republic of Ireland) and fluorescein-12-dUTP (Roche, Lewes, UK) according to manufacturers’ instructions at 37 °C for 1 h. Sections were counter-stained with Hoechst (1 µg/mL) to visualize the nuclei, mounted and viewed under a fluorescence microscope (Leica DM LB2; Leica, Nussloch, Germany).

2.7. Immunofluorescent staining

Frozen sections were brought to room temperature, rehydrated in PBS (137 mM NaCl, 2.7 mM KCl, 10 mM NaPO4, 1.8 mM KH2PO4), permeabilized in PBS with 5% donkey serum and 0.1% Triton X-100 for 30 min at room temperature, followed by blocking in PBS with 5% donkey serum. Subsequently, sections were incubated with primary antibody or lectin solutions overnight at 4 °C (Table 1). Antibody binding was detected by using conjugated secondary antibodies (Alexa Fluor 488; Invitrogen, Carlsbad, CA) at a dilution of 1/500 for 1 h at room temperature. Sections incubated with secondary antibody-only confirmed positive immunolabelling with primary antibodies (data not shown). Hoechst 33,342 (1 µg/mL; Sigma-Aldrich) was used to counterstain the nuclei. Sections were mounted with Mowiol mounting medium (Sigma-Aldrich) and viewed under a fluorescence microscope (Leica DM LB2; Leica).

2.8. Assessment of ROS using dihydroethidium (DHE)

Intracellular ROS were evaluated in situ using dihydroethidium (DHE), as previously described [40–42]. Once in contact with superoxide radicals, DHE is converted to ethidium which intercalates with DNA and emits red fluorescence at approximately 600 nm. Following light-damage, mice received two intraperitoneal injections of 20 mg/kg DHE (Molecular Probes, Life Technologies), 30 min apart. Sections were carried out 3.5/4 h prior to euthanasia, using as little light as possible. Mice were then returned to the dark until euthanized; at 6, 24 or 48 h post-light-damage. Eyes were enucleated, fixed, cryo-sectioned and re-hydrated as described above, followed by counter-staining with DHE.

Table 1

<table>
<thead>
<tr>
<th>Antibody/ Lectin</th>
<th>Supplier</th>
<th>Catalogue #</th>
<th>Dilution/ Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>PNA-FITC</td>
<td>Vector Laboratories</td>
<td>FL-1071</td>
<td>1:500</td>
</tr>
<tr>
<td>Rhodopsin</td>
<td>EMDMillipore</td>
<td>AB9279</td>
<td>1:200</td>
</tr>
<tr>
<td>Nrf2</td>
<td>Abcam</td>
<td>ab11316</td>
<td>1:200 IP</td>
</tr>
<tr>
<td>SOD2</td>
<td>Abcam</td>
<td>ab13553</td>
<td>1:200</td>
</tr>
<tr>
<td>SOD1</td>
<td>Abcam</td>
<td>ab13498</td>
<td>1:200</td>
</tr>
<tr>
<td>phospho-Nrf2</td>
<td>Abcam</td>
<td>Ab76626</td>
<td>1:100 IP</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Cell Signaling</td>
<td>5174</td>
<td>1:1000</td>
</tr>
<tr>
<td>Histone H3</td>
<td>Abcam</td>
<td>Ab12079</td>
<td>1 µg/mL</td>
</tr>
</tbody>
</table>
primary antibody or TUNEL, and Hoechst; as described in Immunofluorescent Staining above. DHE staining was examined in the red channel; excitation: 543 nm, emission > 590 nm.

2.9. Flow cytometry

2.9.1. Single cell suspension preparation and assessment of cell viability

Following euthanasia, the retinas from enucleated eyes were dissected in cold Dulbecco’s modified Eagle medium (DMEM) under as little light as possible. Single-cell suspensions (SCSs) were made by digesting each retina in 2.5 mL of Trypsin-EDTA solution (0.25%) containing 50 μL deoxyribonuclease II (DNaseII) (10,000 units/mL) from bovine spleen (both Sigma, Arklow, Ireland) for 15 min at 37 °C. This solution was then decanted, and 2.5 mL DMEM containing 50 μL DNase II was added to retinas. Homogenization was performed by pipetting up and down 10 times using a Pasteur pipette. Large debris was allowed to settle, and 2 mL of single-cell suspension were collected and placed into a FACS tube (BD Biosciences) to be loaded with MitoSox. The cell viability of the SCSs was assessed by tryphan blue-exclusion assay (Sigma, cat.# 15250061) using a haemocytometer.

2.9.2. Assessment of SCS quality

To verify the SCSs comprised intact rather than fragmented cells, cytospin preparations were made using 200 μL of each SCS with a Shandon CytoSpin 11 Cytocentrifuge (Shandon). Cytospins were then incubated with rhodopsin antibody (Table 1) and Hoechst 33,342 (Sigma, cat# Z359971). Cellular fractions were prepared according to kit instructions, with replacement of the Halt™ Protease Inhibitor Cocktail (included in the kit), with Halt™ Protease and Phosphatase Inhibitor Cocktail (Sigma, cat#78440). Total protein concentration of each fraction was determined by Bradford assay, using BSA as standard. Equivalent amounts of protein were resolved on sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) in 4X Protein Loading Buffers (LI-COR, cat# P/N 928-40004) and then transferred onto nitrocellulose membranes (Schleicher & Schuell, Whatman, Dassel, Germany). Membranes were blocked with Odyssey TBS Blocking Buffer (LI-COR, cat# P/N 927–50000) for 1 h at RT and then incubated at 4 °C overnight with primary antibody (Table 1). Membranes were subsequently washed three times for 5 min in Tris-buffered saline/0.1% Tween-20 (TBST) before adding appropriate Alexa Fluor fluorescent secondary antibodies diluted 1:10,000, in Odyssey TBS Blocking Buffer/TBST solution. Blots were scanned using the Odyssey Infrared Imaging System (LI-COR Biosciences, UK) for fluorescent detection of the secondary antibodies. Fluorescence signal intensity was quantified using Image Studio Lite software (LI-COR Biosciences, UK).

2.12. Statistical analyses

Student’s t-test assuming unequal variances was used to determine whether there was a significant difference between the two sample means.

3. Results

3.1. Norgestrel rescues photoreceptor cells from light-induced ROS production and subsequent cell death

We have previously described how norgestrel protects photoreceptor cells from light-induced cell death [37]. To investigate whether norgestrel also reduces light-induced ROS, vehicle or norgestrel treated mice were light-damaged (LD) and subsequently given intraperitoneal injections of dihydroethidium (DHE). DHE is a sensitive indicator of oxidative stress [44]. TUNEL within the ONL shows photoreceptor cell death in vehicle treated mice at 24 h and 48 h post-LD, which is also inhibited by norgestrel, as expected. The ONL is visibly thinner in vehicle treated mice 24 h and 48 h after LD, as assessed by Hoechst staining of cell nuclei. ONL thickness was measured to quantify the reduction in cell death due to norgestrel (Fig. 2B).

3.2. Norgestrel rescues light-induced photoreceptor morphological damage

We have previously shown that norgestrel preserves photoreceptor morphology in the rd10 model of RP, which translates into preservation of function as measured by electroretinograms [37]. Here, we sought to investigate if light-damage (LD) induces structural damage to the photoreceptors similar to the disease model, whether this correlates with ROS production, and whether norgestrel can prevent such damage. The morphology of the photoreceptors was investigated at 24 and 48 h post-LD (Fig. 2); the times at which cell death is observed (Fig. 1). Rod morphology was assessed by immunofluorescent staining.
A.  

<table>
<thead>
<tr>
<th>Hoechst</th>
<th>Hoechst + TUNEL</th>
<th>Hoechst + DHE</th>
</tr>
</thead>
<tbody>
<tr>
<td>veh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>norg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6 h

<table>
<thead>
<tr>
<th>Hoechst</th>
<th>Hoechst + TUNEL</th>
<th>Hoechst + DHE</th>
</tr>
</thead>
<tbody>
<tr>
<td>veh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>norg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

24 h

<table>
<thead>
<tr>
<th>Hoechst</th>
<th>Hoechst + TUNEL</th>
<th>Hoechst + DHE</th>
</tr>
</thead>
<tbody>
<tr>
<td>veh</td>
<td></td>
<td></td>
</tr>
<tr>
<td>norg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

48 h

B

24 h LD

48 h LD
with anti-rhodopsin (Rho), while cone morphology was assessed by staining with the lectin peanut agglutinin (PNA). PNA binds specifically to carbohydrates on the plasma membranes of cone inner and outer segments, as well as their synaptic pedicles that reside within the outer plexiform layer (OPL) [45].

LD markedly reduced photoreceptor cell density in vehicle (veh) treated mice compared to those that received norgestrel (norg), with the remaining photoreceptor layer displaying abnormalities in length and structure (Fig. 2Ai, ii and Bi, ii, upper panels). By 24 h post-LD, cone cells had begun breaking down in vehicle treated mice, becoming fragmented and swollen in appearance (Fig. 2Ai, upper panels), a phenomenon shown to occur in the rd10 model of RP [46]. By 48 h, this aberrant morphology was more advanced, with no synaptic pedicles visible in the OPL (Fig. 2Bi, upper panels). In contrast, cone cell structure was preserved following LD in norgestrel treated mice, with cells retaining their characteristic neuronal morphology (Fig. 2Ai, Bi, lower panels).

At 24 h post-LD rod cell morphology appears more abnormal than that of cones in vehicle treated mice (Fig. 2Aii, upper panels), in accordance with the disease model of RP where cone cell death is secondary to that of rods [3,4]. Rhodopsin is expressed in rod outer segments, but immunoreactivity appears closer to the ONL in vehicle compared to norgestrel treated mice, (Fig. 2Aii, Bi, top panels). This suggests that rhodopsin has de-localized to the inner segments, a phenomenon also observed during retinal degeneration in inherited RP models [47]. By 48 h, rhodopsin immunoreactivity is reduced in vehicle compared to norgestrel treated mice (Fig. 2Bi), as rod cell death increases. At both time-points, norgestrel restores rod morphology; with uniform rhodopsin staining that is localized further from the ONL (Fig. 2Aii, Bi, lower panels). Counter-staining of DHE with PNA or rhodopsin illustrates that ROS production correlates with morphological changes to the photoreceptors.

### 3.3. Norgestrel reduces light-induced mitochondrial ROS

Photoreceptors have a densely packed population of mitochondria within their inner segments, and as such have a high metabolic demand [48]. This demand is met by mitochondrial oxidative phosphorylation (OXPHOS), perturbation of which generates excess levels of ROS and is implicated in various neurodegenerative diseases, including RP [49]. To determine if norgestrel can reduce light-induced mitochondrial-specific ROS, flow cytometry was carried out using single-cell suspensions (SCSs) from retinas of light-damaged (LD) mice loaded with the fluorescent probe MitoSox (Fig. 3). MitoSox is a modified derivative of DHE, which is targeted specifically to the mitochondria [50]. Upon oxidation, MitoSox is converted to mito-2-hydroethidium, which binds mitochondrial DNA and emits a red fluorescence [51]. Unlike DHE, MitoSox cannot be administered to live animals, hence this approach was taken. Initially, the photoreceptor population was identified by carrying out flow cytometry on retinas of untreated LD mice (48 h post-LD) compared with untreated mice which were not subjected to LD (healthy) (Fig. 3A). 10,000 events were counted in both samples. The population present in the healthy cells (78.8%) (Fig. Aii), that had reduced (16.6%) in the LD mice (figure Aii), was deemed to be photoelectors based on the results in Fig. 1, in which cell death is exclusively visualized within the ONL by TUNEL assay. This region was gated in all subsequent experiments. Following LD, MitoSox fluorescence is reduced in norgestrel treated mice at 6 h (Fig. 3Bi), 24 h (Fig. 3Ci) and 48 h (Fig. 3Di) as represented by histogram overlays. Taking all experiments, the median fluorescence intensity of MitoSox was significantly different between vehicle and norgestrel treated mice at 6 h; p < 0.001 (Fig. 3Bii), 24 h; p < 0.0042 (Fig. 3Cii) and 48 h p = < 0.0044 (Fig. 3Di).

To ensure the retinal cells remained viable following the SCS preparation tryphan blue-exclusion assays were performed. This test is based on the concept that viable healthy cells do not take up impermeable dyes, whereas dead or compromised cells do. Cell viability was found to be approximately 80% (Fig. 3E).

To further validate the quality of the SCS preparations, and to ensure cells remain intact without becoming fragmented, cytopsins were made using SCSs from retinas of healthy mice. Rhodopsin immunoreactivity merged with Hoechst staining verified the photoreceptor cells were indeed intact (Fig. 3Fi–iii).

### 3.4. Norgestrel increases the expression of Nrf2 and SOD2, but not SOD1

We next sought to investigate if the antioxidant effects of norgestrel following LD include modulation of the expression of Nrf2 and its effector proteins SOD1 and SOD2. Nrf2 was chosen as it is often the first port of call when cells come under oxidative stress, and along with the SODs has been shown to be regulated by progesterone [31–35]. SOD1 and SOD2 scavenge hydrogen peroxide in the cytosol and mitochondria respectively [52,53]. Employing immunofluorescence staining of retinal sections, we found that norgestrel markedly increases both Nrf2 and SOD2 expression in photoreceptor cells. Nrf2 Immunoreactivity is increased in the photoreceptor layer (PRL) at 6 h (Fig. 4Ai), 24 h (Fig. 4Bi) and 48 h (Fig. 4Ci) post-LD. SOD2 expression is also increased in the PRL at all time-points studied (Fig. 4A, B, C, ii). Quantification of fluorescence intensity shows that these increases in Nrf2 and SOD2 are significant at all time-points (Fig. 4D). Norgestrel fails to increase the expression of SOD1 any time post-LD (Figs. Ai, Bi and Ci). ROS were also visualized by DHE fluorescence.

### 3.5. Norgestrel modulates Nrf2 expression at the post-translational level

We lastly sought to investigate the mechanism of Nrf2 up-regulation by norgestrel. Firstly, we looked at the effect of norgestrel on Nrf2 transcription by means of quantitative real time PCR (qRT-PCR). At all time-points post-LD, no change was observed in nrf2 expression between vehicle and norgestrel treated mice (Fig. 5A). Next, we investigated the effect of norgestrel on Nrf2 at the post-translational level. Indeed, Nrf2 is regulated mainly at the post-translational level. It is constitutively expressed, and under basal conditions the majority of the population is bound to the inhibitor KEAP1, which sequesters Nrf2 within the cytoplasm and promotes its constant degradation by the ubiquitin protease system (UPS) via the E3 ligase Cul-3 [54]. In response to stimuli Nrf2 can also be activated in various ways, including phosphorylation. Nrf2 contains many potential phospho-sites, which may be targets for different kinases [55]. One verified Nrf2 kinase is protein kinase C (PKC) which phosphorylates Nrf2 on serine 40 (S40), thereby disrupting its interaction with KEAP1, and enabling it to translocate into the nucleus [56,57].

---

[Fig. 1. Norgestrel prevents light-induced ROS production and subsequent cell death. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. Approximately 4 h before euthanasia, mice received two intraperitoneal injections of 20 mg/kg dihydroethidine (DHE), 30 min apart. Ocular sections were prepared and assessed by microscopy as described in Methods. A; DHE fluorescence (red), indicative of ROS production, and TUNEL staining (green), indicative of cell death, were assessed in the retinas of mice treated with vehicle (veh) or norgestrel (norg) at 6 h (Ai), 24 h (Aii) and 48 h (Aiii) post-LD. Hoechst staining of retinal nuclei allows orientation of retinal layers, and shows changes in the thickness of the ONL following LD. B; graphical representation of ONL thickness at 24 and 48 h post-LD in vehicle (veh) or norgestrel (norg) treated mice. RPE; retinal pigment epithelium, PRL; Photoreceptor layer, ONL; outer nuclear layer, INL; inner nuclear layer, RGL; retinal ganglion cell layer. Images are representative of at least n=3. Error bars denote ± SEM from three independent experiments Scale bar=50 µm. *p < 0.05. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)]
whether norgestrel has any effect of Nrf2 phosphorylation and thus nuclear translocation. Cytosolic and nuclear fractions from whole retinal lysates of mice treated with vehicle (veh) or norgestrel (norg) prior to LD were probed for pNrf2 (S40) expression by means of western blot analysis (Fig. 5B). pNrf2 is markedly increased in the nuclear fractions at all times post-LD following norgestrel treatment, while total Nrf2 is only marginally increased, or not at all by 48 h. We then employed immunofluorescent staining of retinal sections to look at the expression of pNrf2 in the photoreceptors specifically (Fig. 5C). Compared to vehicle treated mice, norgestrel elevated the levels of pNrf2 within the ONL at 6 h (Fig. 5Ai), 24 h (Fig. 5Aii) and 48 h (Fig. 5Aiii).
Fig. 3. Norgestrel decreases light-induced mitochondrial ROS. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. Retinas were removed from the eyes, digested and homogenized into single-cell suspensions (SCSs) and loaded with MitoSox, as described in Methods. MitoSox fluorescence was assessed by flow cytometry. A; initially, the photoreceptor population was identified by counting 10,000 events in SCSs from un-treated healthy mice (i) or un-treated mice 48 h after being subjected to LD (ii). Forward scatter (FSC) plotted against side scatter (SSC) shows the photoreceptor (PR) cell population in healthy mice (78.8%) (Ai) is dramatically reduced (16.6%) in the retinas of LD mice (Aii). B (6 h); C (24 h); D (48 h); representative histogram overlays show MitoSox fluorescence in norgestrel (norg) treated mice compared to vehicle (veh) (i). Graphical representations of the median fluorescence intensity (MFI) of MitoSox in vehicle (veh) or norgestrel (norg) treated mice (ii). E; cell viability of the SCSs was measured by tryphan blue-exclusion assay. F; cytospin preparations of SCSs from healthy mice were assessed for rhodopsin immunoreactivity and visualized at 40× magnification (i, ii) (scale bar=50 µm) or 10× magnification (iii) (scale bar=25 µm). All results are representative of at least n=3. **p<0.01, ***p<0.001. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
4. Discussion

Photoreceptor cell death is the collective end-point for all cases of RP, irrespective of the underlying genetic cause. As RP progresses, photoreceptor degeneration is reduced due to the disease-causing mutation and the rod photoreceptors cannot utilize the oxygen available to them. As the photoreceptor layer becomes progressively more disorganized this is potentiated, resulting in hyperoxia within the outer retina and the consequent initiation of cell death pathways [58,59]. Although the disease-causing mutation resides within rod genes, it is the secondary loss of cones that leads to total blindness. The mechanism behind this is not fully understood, but it is known that oxidative stress is a key factor [6–8,41,60]. Gene therapy is a promising therapeutic approach for RP, however targeting the multitude of RP-related genes is complex.

The cone photoreceptor is a potent neuroprotective agent, and has recently been shown to reduce oxidative stress in a model of repeated mild brain injury [35]. We have previously demonstrated how the synthetic progestin norgestrel is neuroprotective in the compromised retina using the rd10 model of RP, and the light-damage model of retinal degeneration [36,37]. Norgestrel acts via upregulation of the neurotrophic factors bFGF and LIF, the latter being a potent neurotrophic factor which, interestingly, has been shown to have antioxidant effects in the retina [61]. Here, we further expand on the neuroprotective actions of norgestrel in the retina, investigating its effects on oxidative stress using the light-damage model of retinal degeneration, a well-established paradigm [62]. Light-damage caused the production of intracellular ROS in photoreceptor cells, as visualized by DHE fluorescence, which was prevented by pre-treatment with norgestrel (Fig. 1). Due to the non-specificity of DHE [63], we refer here to the detection of ROS, rather than superoxide. In vehicle-only treated mice, total ROS is evident in the PRL and ONL. Within the PRL, the inner segments of the photoreceptor cells which are high in mitochondria [48], thus DHE fluorescence here is suggestive of mitochondrial ROS. As previously reported [37], norgestrel also inhibited light-induced cell death, as visualized by TUNEL assays. Light-induced ROS production preceded cell death, supporting the hypothesis that oxidative stress is a key contributor to photoreceptor loss.

As RP advances and photoreceptors progressively degenerate, the cells undergo various structural changes. Rod cells exhibit de-localization of rhodopsin [47], while cone inner and outer segments become fragmented and swollen [46]. Cone pedicles are also lost, due to perturbed synaptic connectivity within the OPL [64]. These phenomena, characteristic of structural changes during RP, are observed coinciding with ROS production following light-damage (Fig. 2).

Moreover, abnormalities in rod cell structure appear more advanced than that of cones at 24 h post light-damage (Fig. 2A), as is observed in RP models, where ROS derived from dying rod cells is a key factor in cone cell death [6,10,11]. All structural aberrations were completely prevented by norgestrel; which maintained normal photoreceptor morphology and ONL thickness (Fig. 2).

Having looked at total intracellular ROS using DHE, we sought to investigate whether mitochondrial-derived ROS plays a part in light-induced photoreceptor degeneration (Fig. 3). Indeed, it has been shown to play a major role in the development of other retinopathies, with studies suggesting that mitochondrial-derived superoxide is the primary source of ROS in diabetic tissue, and is responsible for initiating other ROS signaling pathways [65,66]. We show here that light-damage indeed generates the production of mitochondrial ROS within the photoreceptors which is significantly reduced by norgestrel (Fig. 3B). Unlike the complete inhibition of DHE fluorescence (Fig. 1), norgestrel did not abolish MitoSox fluorescence. The difference here is likely due to that fact that flow cytometry is a far more sensitive application. Also, the preparation of single-cell suspensions may introduce ROS, and the reduction of light-induced mitochondrial-ROS by norgestrel may appear greater if it could be assessed in situ. Again, like DHE, MitoSox is a non-specific superoxide probe [63], and so we refer to the detection of general ROS.

Having established that norgestrel can reduce mitochondrial-ROS within photoreceptors, we sought to investigate the mechanism behind this. Given that the KEAP1-Nrf2 pathway is one of the most important in protecting retinal cells from endogenous- and exogenous-induced oxidative stress [26], and that Nrf2 is paramount to normal mitochondrial function [67], we looked at the expression of Nrf2 in the stressed retina following norgestrel treatment. To date, most studies on Nrf2 in the context of retinopathies have been done using AMD models, where photoreceptor loss is secondary to degeneration of the retinal pigment epithelium (RPE). It has been shown that the aging RPE exhibits dysregulated Nrf2 signaling, leading to impaired induction of antioxidant genes [68], while knockout of Nrf2 in otherwise healthy mice increases the susceptibility of the outer retina to age-related degeneration [69]. Similarly, activation of Nrf2 by administration of sulforaphane has been shown to protect RPE cells from photo-oxidative damage [70]. Here, we investigated the expression of Nrf2 in photoreceptors following light-induced oxidative stress. While minimal Nrf2 was observed in vehicle treated mice at 6 h post light-damage, with none at 24 h or 48 h, norgestrel induced Nrf2 expression in the photoreceptor layer and sustained it for at least 48 h following the insult (Fig. 4Ai, Bi and Ci).

Following on from this, we examined the expression of two key Nrf2 effectors, SOD1 and SOD2, which catalyze the conversion of superoxide to hydrogen peroxide. SOD1 is cytosolic, whereas SOD2 is localized in the mitochondrial matrix [71]. While SOD1 expression was not increased (Fig. 4 Aiii, Biii and Ci iii), SOD2 immunoreactivity was markedly elevated in the photoreceptor inner segments, where the mitochondria reside (Fig. 4 Ai, Bi and Ci). Previous studies have demonstrated the importance of both enzymes in maintaining the retinal redox environment; however SOD2 appears to be more important for photoreceptor homeostasis. In Sod1 knockout mice, Hashizume and colleagues observed delayed changes in the retinal architecture compared to wt mice [72]. Inner nuclear layer (INL) thinning became significant (p < 0.01) at 30 weeks of age, while a less significant (p < 0.05) decrease in ONL thickness was observed only at 50 weeks of age, suggesting that SOD1 is more important for the health of the INL, rather than the photoreceptors. Indeed, the loss of cells in the outer retina may be a consequence of inner retinal cell death. In comparison to this slow and progressive degeneration which affects mainly the inner layers of the retina, Sod2 knockout mice show photoreceptor degeneration from 9 days old, compared to their wild type counterparts [73]. Further support for this hypothesis comes from...
Fig. 5. Norgestrel increases phosphorylation of Nrf2 and its nuclear translocation. Balb/c mice were given intraperitoneal injections of vehicle (veh) or vehicle containing 100 mg/kg norgestrel (norg) 1 h prior to light damage (LD) and were euthanized at 6 h, 24 h or 48 h post-LD. A; LD retinas were assessed for relative changes in nrf2 mRNA expression following vehicle (veh) or norgestrel (norg) treatment. Relative expression was analyzed by means of real time (rt) PCR, with fold change compared to the geometric mean of three endogenous reference genes (gapdh, hprt, β-actin). Results are representatives of n=2. B; sub-cellular fractionation was carried out on retinal lysates from mice treated with vehicle (veh) or norgestrel (norg) and euthanized 6 h, 24 h and 48 h post-LD. Expression of phospho-Nrf2 (pNrf2) or total Nrf2 (Nrf2) in cytosolic and nuclear fractions was assessed by means of western blot analyses. Equal loading of samples and verification of the subcellular fractions were assessed by probing for cytosolic-localized GAPDH and nuclear-localized histone H3 (HH3). Western blot is representative of n=4. C; Approximately 4 h before being euthanized, mice received two intraperitoneal injections of 20 mg/kg dihydroethidine (DHE), 30 min apart. Ocular sections were obtained and assessed by microscopy as described in Methods. pNrf2 expression (green) was assessed in vehicle (veh) or norgestrel (norg) treated mice at 6 h (Ci), 24 h (Cii) and 48 h (Ciii) post-LD. Counter-fluorescence of DHE (red) is also shown. Hoechst staining (blue) allows orientation of the retinal layers, but is removed from half of each image to increase the clarity of pNrf2 staining. PRL; Photoreceptor layer, ONL; outer nuclear layer. Images are representative of at least n=3. Scale bar=50 µm. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
a number of studies where SOD1 was found to be an important antioxidant in the retinal ganglion cell (RGC) layer, the innermost layer of the retina. SOD1-deficient mice display increased ROS levels in the RGC layer [74]. In another study, Sod1-null mice in which retinal oxidative stress was induced, displayed TUNEL in the INL and RGCs only [75]. Interestingly, Sod1 overexpressing mice have actually been shown to display increased levels of ROS with accelerated photoreceptor degeneration [5]. The results presented here suggest that mitochondrial-derived ROS is an important consequence of light-induced retinal damage, and that norgestrel can markedly reduce this toxicity via up-regulation of Nrf2 and subsequently SOD2, enabling detoxification within the mitochondria which is necessary for preservation of photoreceptor cell number and structure.

We next sought to investigate the mechanism of norgestrel-induced Nrf2 expression. We first examined nrf2 mRNA expression following norgestrel, but found no change compared to vehicle (Fig. 5A). Although norgestrel is a synthetic steroid hormone, lack of transcriptional activity is not surprising given that it can act through the non-classical receptor; progesterone receptor membrane component 1 (PGMRC1) [76]. Moreover, Nrf2 is known to be regulated almost entirely at the post-translational level, being constitutively expressed and maintained at basal levels by KEAP1-mediated turn-over [54]. Such basal expression enables Nrf2 to elicit a rapid and efficient response to stress stimuli, upon which it escapes KEAP1 and translocates into the nucleus, bringing about transcription of various anti-oxidant genes. A small population of Nrf2 is also believed to remain in the nucleus, allowing constitutive basal expression of target genes [77,78]. Cytosolic Nrf2 can be phosphorylated and thus activated by PKC, which disrupts its interaction with KEAP1 [56,57]. Following light-induced damage, norgestrel treated retinas display an elevated population of phospho-Nrf2 within the nucleus (Fig. 5B). However, the western blot analyses are that of whole retinas. Looking specifically at the photoreceptors, there are marked increases in pNrf2 levels within the ONLs of norgestrel treated mice, which is sustained up to 48 h (Fig. 5C). These data suggest that norgestrel mediates the activation of Nrf2 through PKC-phosphorylation, thereby bringing about an increase in Nrf2 nuclear translocation and consequent antioxidant gene transcription. Further work needs to be carried out to explore the link between norgestrel and PKC, however other studies have shown that progesterone can exert neuroprotective effects via activation of PKC [79,80].

Nrf2 also contains a phoshodegron, phosphorylation of which promotes nuclear export and a return to basal antioxidant signaling. A central regulator of Nrf2 in this manner is glycosyn acthase kinase 3β (GSK3β) [55]. GSK3β phosphorylates and thus activates cytosolic Fyn, allowing it to enter the nucleus where it in turn phosphorylates and brings about the nuclear export of Nrf2 [81–83], resulting in Nrf2 re-binding KEAP1 and being rapidly degraded. Interestingly, we have previously shown that norgestrel inhibits GSK3β [84], adding weight to the results reported here.

In conclusion, this study supports previous work showing that norgestrel is a potent neuroprotective agent in the compromised retina, and provides strong in vivo evidence that norgestrel is also a powerful antioxidant. We show how norgestrel markedly reduces mitochondrial-derived ROS in the retina via post-translational regulation of the major antioxidant transcription factor Nrf2 and its effector protein SOD2. These results highlight the potential of norgestrel as a therapeutic option for RP and other retinal degenerative conditions, which will not discriminate between genetic etiologies.

Conflict of interest

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors gratefully acknowledge all members of the Biologic Services Unit (BSU) for technical assistance, and Dr. Francesca Doonan for invaluable advice. This work was supported by Science Foundation Ireland (SFI) (grant no. 13/IA/1783), and Fighting Blindness (registered charity number 20013349).

References
